Aprea Therapeutics (NASDAQ:APRE) PT Raised to $11.00 at Wedbush

Aprea Therapeutics (NASDAQ:APREGet Free Report) had its target price lifted by research analysts at Wedbush from $9.00 to $11.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price target suggests a potential upside of 64.42% from the company’s current price. Wedbush also issued estimates for Aprea Therapeutics’ Q1 2025 earnings at ($1.00) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.31) EPS and FY2028 earnings at $0.81 EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a report on Tuesday.

View Our Latest Report on APRE

Aprea Therapeutics Trading Up 10.2 %

NASDAQ:APRE opened at $6.69 on Wednesday. Aprea Therapeutics has a twelve month low of $2.78 and a twelve month high of $8.85. The company has a market cap of $25.02 million, a P/E ratio of -1.68 and a beta of 1.05. The company’s 50-day moving average price is $6.36 and its 200-day moving average price is $4.99.

Insider Buying and Selling

In related news, Director Bernd R. Seizinger acquired 6,860 shares of the business’s stock in a transaction dated Wednesday, March 13th. The shares were acquired at an average cost of $7.29 per share, for a total transaction of $50,009.40. Following the acquisition, the director now directly owns 33,685 shares in the company, valued at approximately $245,563.65. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have acquired 9,870 shares of company stock worth $71,952 in the last three months. Corporate insiders own 20.90% of the company’s stock.

Institutional Trading of Aprea Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Aprea Therapeutics by 26.9% in the fourth quarter. Vanguard Group Inc. now owns 34,688 shares of the company’s stock valued at $163,000 after acquiring an additional 7,347 shares in the last quarter. Royal Bank of Canada lifted its stake in Aprea Therapeutics by 13,788.0% during the fourth quarter. Royal Bank of Canada now owns 44,025 shares of the company’s stock worth $207,000 after purchasing an additional 43,708 shares during the last quarter. Geode Capital Management LLC bought a new position in Aprea Therapeutics during the second quarter worth $74,000. Millennium Management LLC lifted its stake in Aprea Therapeutics by 35.7% during the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock worth $53,000 after purchasing an additional 43,293 shares during the last quarter. Finally, BNP Paribas Arbitrage SNC bought a new stake in Aprea Therapeutics in the third quarter valued at $40,000. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

(Get Free Report)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.

Featured Articles

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.